131 related articles for article (PubMed ID: 14768718)
1. Lifetime health effects and costs of diabetes treatment.
Niessen LW; Dijkstra R; Hutubessy R; Rutten GE; Casparie AF
Neth J Med; 2003 Nov; 61(11):355-64. PubMed ID: 14768718
[TBL] [Abstract][Full Text] [Related]
2. Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy.
Palmer AJ; Roze S; Valentine WJ; Minshall ME; Lammert M; Nicklasson L; Spinas GA
Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S67-73. PubMed ID: 15324518
[TBL] [Abstract][Full Text] [Related]
3. Stochastic league tables: an application to diabetes interventions in the Netherlands.
Hutubessy RC; Niessen LW; Dijkstra RF; Casparie TF; Rutten FF
Health Econ; 2005 May; 14(5):445-55. PubMed ID: 15386648
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
[TBL] [Abstract][Full Text] [Related]
5. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
[TBL] [Abstract][Full Text] [Related]
6. What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model.
Palmer AJ; Roze S; Valentine WJ; Minshall ME; Lammert M; Oglesby A; Hayes C; Spinas GA
Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S59-66. PubMed ID: 15324517
[TBL] [Abstract][Full Text] [Related]
7. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
Sorensen SV; Frick KD; Wade A; Simko R; Burge R
Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
[TBL] [Abstract][Full Text] [Related]
8. Using costs in cost-effectiveness models for chronic diseases: lessons from diabetes.
Hoerger TJ
Med Care; 2009 Jul; 47(7 Suppl 1):S21-7. PubMed ID: 19536014
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
[TBL] [Abstract][Full Text] [Related]
10. The costs and benefits of enhanced depression care to employers.
Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R
Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009
[TBL] [Abstract][Full Text] [Related]
11. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
Ali M; White J; Lee CH; Palmer JL; Smith-Palmer J; Fakhoury W; Valentine WJ
J Med Econ; 2008; 11(4):651-70. PubMed ID: 19450074
[TBL] [Abstract][Full Text] [Related]
12. The economic analyses of the UK prospective diabetes study.
Gray AM; Clarke P
Diabet Med; 2008 Aug; 25 Suppl 2():47-51. PubMed ID: 18717979
[TBL] [Abstract][Full Text] [Related]
13. Economics of diabetes mellitus.
Krein SL; Funnell MM; Piette JD
Nurs Clin North Am; 2006 Dec; 41(4):499-511, v-vi. PubMed ID: 17059971
[TBL] [Abstract][Full Text] [Related]
14. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
[TBL] [Abstract][Full Text] [Related]
16. The costs, effects and cost-effectiveness of counteracting overweight on a population level. A scientific base for policy targets for the Dutch national plan for action.
Bemelmans W; van Baal P; Wendel-Vos W; Schuit J; Feskens E; Ament A; Hoogenveen R
Prev Med; 2008 Feb; 46(2):127-32. PubMed ID: 17822752
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of community-based physical activity interventions.
Roux L; Pratt M; Tengs TO; Yore MM; Yanagawa TL; Van Den Bos J; Rutt C; Brownson RC; Powell KE; Heath G; Kohl HW; Teutsch S; Cawley J; Lee IM; West L; Buchner DM
Am J Prev Med; 2008 Dec; 35(6):578-88. PubMed ID: 19000846
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design.
Sullivan MD; Anderson RT; Aron D; Atkinson HH; Bastien A; Chen GJ; Feeney P; Gafni A; Hwang W; Katz LA; Narayan KM; Nwachuku C; O'Connor PJ; Zhang P;
Am J Cardiol; 2007 Jun; 99(12A):90i-102i. PubMed ID: 17599429
[TBL] [Abstract][Full Text] [Related]
19. Lipid-lowering treatment for all could substantially reduce the burden of macrovascular complications of diabetes patients in the Netherlands.
Jacobs-van der Bruggen MA; Engelfriet PM; Hoogenveen RT; van Baal PH; Struijs JN; Verschuren WM; Smit HA; Baan CA
Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):521-5. PubMed ID: 18830084
[TBL] [Abstract][Full Text] [Related]
20. Economic costs of diabetes in the U.S. In 2007.
American Diabetes Association
Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
